3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN	Disease Attributes, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor	Active, not recruiting	Phase 1	2026-04-06		NCT01822652

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Baylor College of Medicine	267
Center for Cell and Gene Therapy, Baylor College of Medicine	40
Kids Cancer Research Foundation	1
National Cancer Institute (NCI)	3015
Solving Kids' Cancer	2
The Evan Foundation	3
The Methodist Hospital Research Institute	124

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Houston Methodist Hospital	Houston	United States	260
Texas Children's Hospital	Houston	United States	187